Bayer to present extensive new data from its oncology portfolio at ESMO 2024
Not intended for U.S. and UK Media
Bayer will reveal late-breaking data from the Phase III ARANOTE trial in metastatic hormone-sensitive prostate cancer for darolutamide / Late-breaking data from the PEACE-III study of the first and only approved targeted alpha therapy radium-223 …
Bayer to unveil new data from its Phase III OASIS 3 long-term study of elinzanetant in the treatment of vasomotor symptoms associated with menopause
Not intended for UK Media – The Menopause Society Annual Meeting 2024:
Detailed results from the Phase III OASIS 3 study evaluating the efficacy and long-term safety of investigational compound elinzanetant will be presented for the first time at this year’s Annual Meeting of The Menopause Society (TMS) / First …
Bayer launches new healthy-aging ecosystem for consumers
Helping consumers better manage their aging journey
Ecosystem includes scientifically formulated cell health support dietary supplement from One A Day® with a wellness companion app and biological age test brought to consumers by Chronomics / Marks the first holistic offering from …
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases / Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and …
Late-Breaking data from finerenone pooled analysis on cardiovascular and kidney outcomes and mortality in high-risk patient populations presented at ESC Congress 2024
Not intended for U.S. and UK Media
In FINE-HEART, the incidence for the primary endpoint of cardiovascular (CV) death was numerically lower in patients treated with finerenone versus placebo, but narrowly missed statistical significance / FINE-HEART is a prespecified pooled …
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure with high unmet medical need
Not intended for U.S. and UK - Media Late-Breaking data from pivotal Phase III FINEARTS-HF study presented at ESC Congress 2024
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly …
Bayer starts Phase III trial in non-small cell lung cancer (NSCLC)
Not intended for UK Media
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations / Data from the phase I/II SOHO-01 trial selected for a presidential …
Within the new Golden Ticket program of Bayer, Genvor to receive fully funded access to lab space and equipment in California / Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait …
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology
Not intended for UK Media
lncRNAs represent a new class of therapeutic targets across disease areas, including oncology / Companies to collaborate on jointly developing two first-in-class small molecule programs targeting lncRNAs, further strengthening Bayer’s precision …
Bayer is advancing in studies on heart failure management showcasing late-breaking heart failure data from Phase III study FINEARTS-HF with finerenone
Not intended for U.S. and UK Media - ESC Congress 2024, a scientific congress of the European Society of Cardiology:
In heart failure, a key focus area for Bayer in cardiology, detailed data from the Phase III FINEARTS-HF study evaluating the efficacy and safety of finerenone versus placebo when added to usual therapy in patients with heart failure (HF) and …
The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data
Not intended for UK Media
OASIS 1 and 2 studies demonstrated positive results for investigational compound elinzanetant which met all primary endpoints by significantly reducing frequency and severity of moderate to severe vasomotor symptoms (VMS, also known as hot …